CROWN BIOSCIENCE

Tumor Homograft Models

Immunocompetent models carrying clinically-relevant oncogenic mutations

A JSR Life Sciences Company

Tumor homograft models are homografts of spontaneous or carcinogen induced GEMM tumors grafted in immuno-competent syngeneic hosts. Developed from virtually any GEMM, tumor homografts are broadening the number and molecular pathology of syngeneic models for preclinical I/O research.

Tumor homografts are never passaged *in vitro* or *ex vivo*. As a result, the original tumor histopathology, molecular pathology, and key oncogenic driver mutations are preserved.

This platform offers:

- Unique models, encompassing disease-specific mutations relevant to human cancers

- The predictive power of GEMM combined with operational simplicity required for *in vivo* pharmacology studies

- A fully competent mouse immune system

- Well-characterized models with histopathology, immune checkpoint and SoC benchmarking, and immune profiling data available via our online database IO Murine Models Database

- Scalability that enables large-scale screening

GEMM/carcinogen induced model

Spontaneous disease

Tumor Fragment

Homograft to syngeneic recipient

Tumor Homograft Model

Kras (G12D)/Trp53 null/Pdx1-cre (KPC) tumor homograft model for the evaluation of novel pancreatic ductal adenocarcinoma (PDAC) treatments

Survival (%) vs Treatment Days

- Vehicle 0mg/kg q.d., p.o.
- Treatment 1
- Treatment 2
- Treatment 3

Patient PDAC

Mouse PDAC from KPC GEMM

Subcutaneous homograft tumor

Orthotopic homograft tumor

Get in touch

Sales
US: +1 858 622 2900   busdev@crownbio.com
UK: +44 870 166 6234   www.crownbio.com

Science
consultation@crownbio.com